FIELD: medicine.
SUBSTANCE: present group of inventions refers to medicine, namely to oncology, and concerns the treatment of cancer. For this, an effective amount of NMT inhibitor is administered to a subject deficient in N-myristoyl transferase 2 (NMT2).
EFFECT: it provides the effective treatment of said form of cancer.
61 cl, 6 dwg, 7 ex, 1 tbl
Title | Year | Author | Number |
---|---|---|---|
SYNTHETIC LETHALITY AND TREATMENT OF CANCER | 2013 |
|
RU2676697C2 |
TREATMENT OF B-CELLULAR MALIGNANT TUMORS USING ANTI-CD40L ANTIBODIES IN COMBINATION WITH ANTI-CD20 ANTIBODIES AND/OR BY CHEMOTHERAPY AND RADIOTHERAPY | 2000 |
|
RU2305561C2 |
IMMUNOCYTOKINE FOR ACTIVATION OF HUMAN IL-10Rα RECEPTOR AND ITS USE | 2020 |
|
RU2810750C2 |
METHODS OF TREATING CANCER USING APILIMOD | 2016 |
|
RU2738934C2 |
OLIGONUCLEOTIDE OR ITS FUNCTIONAL HOMOLOG, COMPOSITION CONTAINING IT AND METHOD OF TREATING OF B-LYMPHOID NEOPLASM | 2006 |
|
RU2409672C2 |
OLIGONUCLEOTIDES OR THEIR FUNCTIONAL HOMOLOGUES, COMPOSITION CONTAINING THEM AND METHOD OF TREATING B-CELL TUMOUR | 2006 |
|
RU2413519C2 |
CHIMERIC ANTIGENIC RECEPTORS AIMED AT ANTIGEN OF AGING OF B-CELLS | 2016 |
|
RU2706582C2 |
METHODS AND COMPOSITIONS FOR TREATMENT OF PERSISTENT INFECTIONS | 2016 |
|
RU2746383C2 |
METHOD AND COMPOSITIONS FOR TREATMENT OF PERSISTING INFECTIONS | 2006 |
|
RU2434641C2 |
COMBINED IMMUNOTHERAPEUTIC APPROACH TO CANCER TREATMENT | 2015 |
|
RU2716821C2 |
Authors
Dates
2018-09-05—Published
2012-07-23—Filed